← All trials
NCT05122234
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 10, 2020
- Primary completion
- Jul 30, 2021
- Completion date
- Nov 14, 2021
- First posted
- Nov 16, 2021
- Last posted
- Nov 16, 2021
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of IndonesiaLead sponsor
- University of IndonesiaReponsible party - principal investigator
- University of IndonesiaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.